Side-by-side comparison of AI visibility scores, market position, and capabilities
Tortus AI provides an AI agent that sits alongside clinicians during patient visits, automatically generating clinical notes and handling documentation tasks in real time.
Tortus AI is a healthcare AI company founded in 2022 in London that develops an AI agent designed to reduce the documentation burden on physicians and clinical staff. The platform operates as a persistent AI presence during clinical encounters, listening to patient-clinician conversations and automatically generating structured clinical notes, coding suggestions, referral letters, and other administrative documentation. Unlike simple transcription tools, Tortus AI interprets clinical context to generate documentation that conforms to specialty-specific formats and coding requirements. The company serves NHS trusts and private healthcare organizations in the United Kingdom and is expanding internationally. Physician burnout driven by excessive documentation requirements is a critical healthcare workforce crisis, with doctors spending roughly half their working time on administrative tasks rather than patient care. Tortus AI addresses this directly by taking over documentation workflows and allowing clinicians to focus on clinical reasoning and patient relationships. The company raised $12M and has deployed across multiple clinical specialties including primary care, emergency medicine, and outpatient specialties with strong clinician satisfaction rates.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.